HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Helbert, M Articles by MacCallum, P Search for Related Content PubMed PubMed Citation Articles by Helbert, M Articles by MacCallum, P

Optimising testing for phospholipid antibodies

Department of Immunopathology, St Bartholomews and the London NHS Trust, London EC1A 7BE, UK
Department of Clinical Haematology, Medical Dental School, Queen Mary and Westfield College, London EC1A, UK
Department of Rheumatology, Medical Dental School, Queen Mary and Westfield College
Computer Department, Medical Dental School, Queen Mary and Westfield College

Dr Helbert mrhelbert{at}mds.qmw.ac.uk Aim—To compare anticardiolipin (ACL) and anti-ß2 glycoprotein 1 (ß2gp1) enzyme linked immunosorbent assays (ELISAs) in the diagnosis of antiphospholipid syndrome (APS) and to incorporate these results into a meta-analysis of published data.

Method—Three representative commercial ACL ELISAs and an in house ß2gp1 assay were optimised and then assessed on 124 sera from normal donors, patients with infection, or patients with APS. A Medline search was screened for papers meeting defined criteria to conduct a meta-analysis. The performance of the assays used in this study was included.

Results—A non-quantitative ACL assay performed at least as well as the anti-ß2gp1 assay in the diagnosis of APS. Meta-analysis confirmed that neither assay is perfect, although the anti-ß2gp1 assay had a higher specificity and lower sensitivity than the ACL assay.

Conclusions—The pooled data suggest that the ACL assay is used to investigate thrombosis without overt underlying pathology and that the improved specificity of the anti-ß2gp1 assay is exploited where infection, connective tissue disease, or atheroma are present.

Key Words: antiphospholipid syndrome • anticardiolipin antibodies • anti-ß2 glycoprotein 1 • sensitivity

This article has been cited by other articles:

				M. A. Ozturk, I. C. Haznedaroglu, M. Turgut, and H. Goker Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia Clinical and Applied Thrombosis/Hemostasis, April 1, 2004; 10(2): 89 - 126. [Abstract] [PDF]

				H.A. Schenkein, C.R. Berry, J.A. Burmeister, C.N. Brooks, S.E. Barbour, A.M. Best, and J.G. Tew Anti-cardiolipin Antibodies in Sera from Patients with Periodontitis J. Dent. Res., November 1, 2003; 82(11): 919 - 922. [Abstract] [Full Text] [PDF]